CUSIP No. 72302T100

CUSIP No. 72302T100

Pineapple Express, Inc.’s (the “Issuer”) common stock, $0.0000001 par value per share (the “Common Stock”). The principal executive offices of the Issuer are located at 10351 Santa Monica Blvd., Suite #420, Los Angeles, California 90025.

(a) This statement is being filed by Jaime Ortega (the “Reporting Person”).

(b) The principal business address of the Issuer and the address for the Reporting Person is c/o Pineapple Express, Inc. 10351 Santa Monica Blvd., Suite # 420 Los Angeles, California 90025.

(c) Mr. Ortega’s principal occupation is director and majority owner of Pineapple Ventures, Inc.

(d) The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

(e) The Reporting Person is a citizen of the United States of America.

The shares of Common Stock owned by the Reporting Person were purchased with the Reporting Person’s personal funds. The shares of Series A Preferred Stock reported herein were acquired by the Reporting Person in connection with a Share Exchange Agreement, dated March 19, 2019, as amended on June 26, 2019, by and among the Issuer, Pineapple Ventures, Inc., a California corporation (“PVI”), and the stockholders of PVI, as more fully described in Item 6 of this Schedule 13D.

No borrowed funds were used to purchase such shares.

All of the shares of Common Stock reported herein (collectively, the “Shares”) were acquired for investment purposes.

The Reporting Person intends to evaluate his investment in the Shares on a continual basis. Other than as expressly set forth below, the Reporting Person has no plans or proposals as of the date of this filing that relate to, or would result in, any of the actions enumerated in Item 4(a)-(j) of Schedule 13D. The Reporting Person may engage in communications with one or more stockholders, officers or directors of the Issuer and others, including but not limited to, discussions regarding the Issuer’s operations and strategic direction and ideas that, if effected, could result in, among other things, any of the matters identified in Item 4 of Schedule 13D, including but not limited to debt or equity capital raising transactions, acquisitions, mergers, combinations and other strategic transactions. The Reporting Person reserves their right, based on all relevant factors and subject to applicable law, at any time and from time to time, to review or reconsider their position, change their purpose, take other actions, including to cause or introduce strategic or corporate transactions involving the Issuer or any of its subsidiaries, or one or more of the types of transactions or have one or more the results described in Item 4(a)-(j) of Schedule 13D) or formulate and implement plans or proposals with respect to any of the foregoing.

The Reporting Person from time to time intend to review their investment in the Issuer on the basis of various factors, including whether various strategic transactions have occurred or may occur, the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s securities in general, as well as other developments and other investment opportunities. Based upon such review, the Reporting Person intends to take such actions in the future as they deem appropriate in light of the circumstances existing from time to time, which may include acquisitions of shares of Common Stock or other convertible securities of the Issuer or disposal of all or any portion of the Shares or shares of Common Stock or other securities of the Issuer otherwise acquired by the Reporting Person, either in the open market or privately negotiated transactions, with or without prior notice.

As of the date hereof, Mr. Ortega has beneficial ownership interest of 45,790,000 shares of Common Stock (representing approximately 52.70% of the number of shares of Common Stock issued and outstanding). The percentage with respect to Mr. Ortega’s beneficial ownership is based on 76,890,925 shares of Common Stock of the Issuer, issued and outstanding as of November 13, 2019, together with such number of shares of Common Stock which the Reporting Person has the right to acquire as of the date of hereof or within 60 days thereafter, representing an aggregate of 86,890,925 shares of Common Stock.

Voting Proxy

On March 8, 2017 the Reporting Person executed an Irrevocable Proxy (the “Irrevocable Proxy”) whereby 30,790,000 shares of the Issuer’s Common Stock owned by the Reporting Person are subject to an irrevocable proxy granted by the Reporting Person to Eric Kennedy Esq. in his capacity as a member of the Board of Directors of the Issuer. Mr. Kennedy is permitted to vote such shares in any manner that Mr. Kennedy may determine in his sole discretion to be in the Issuer’s best interest.

In connection with the Irrevocable Proxy, the Reporting Person entered into a 10b5-1Plan effective March 8, 2017 as related to the Issuer’s Common Stock owned by the Reporting Person.

PVI Acquisition

As previously disclosed in the Issuer’s Current Report on Form 8-K filed with the SEC on March 22, 2019, on March 19, 2019, the Issuer entered into a Share Exchange Agreement (the “Agreement”) with PVI, and the stockholders of PVI (the “PVI Stockholders”). Upon execution of the Agreement (the “Closing”), the Issuer acquired 20,000 shares of PVI’s outstanding capital stock (“PVI Shares”), equaling 20% of the outstanding shares of PVI. In consideration for the PVI Shares, the Issuer issued 1,000,000 shares of its Series A Preferred Stock, $0.0000001 par value per share (“Series A Preferred Stock”), to the PVI Stockholders.

Pursuant to the terms of the Agreement, upon the six-month anniversary of the Agreement (the “Second Closing”), and subject to the conditions to closing set forth in the Agreement, the Issuer was to acquire an additional 60,000 PVI Shares, equaling 60% of the outstanding shares of PVI, for a total of 80% of the outstanding shares of PVI, in consideration for an additional 4,000,000 shares of Series A Preferred Stock to be issued to the PVI Stockholders at the time of the Second Closing. The Series A Preferred Stock may, from time to time, be converted by the holder into shares of the Issuer’s Common Stock in an amount equal to ten shares of Common Stock for each one share of Series A Preferred Stock.

On June 26, 2019, the Issuer, PVI and the PVI Stockholders entered into Amendment No. 1 to the Agreement (“Amendment No. 1”) pursuant to which the parties agreed that on the Second Closing, and subject to the conditions set forth in the Agreement, the PVI Stockholders shall deliver an additional 30,000 shares of Capital Stock to the Issuer, and in consideration and exchange for such capital stock, the Issuer shall issue and deliver an additional 1,000,000 shares of Series A Preferred Stock to the PVI Stockholders.

On July 5, 2019, the Issuer, PVI and the PVI Stockholders, and their respective boards of directors waived the remaining conditions to closing as set forth in the Agreement and ratified and approved the Second Closing.

The Reporting Person is a stockholder of PVI and, in connection with the Agreement, as amended, acquired (i) 500,000 Series A Preferred Stock of the Issuer at Closing and (ii) 1,000,000 Series A Preferred Stock of the Issuer at the Second Closing in consideration of the sale of PVI to the Issuer. In connection with the Closing, the Reporting Person elected to convert 500,000 of his Series A Preferred Stock into the Issuer’s Common Stock effective as of March 28, 2019. The shares of Common Stock reported herein were issued on April 2, 2019.

THE FOLLOWING MATERIALS ARE FILED AS EXHIBITS TO THIS SCHEDULE 13D:

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.